These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 9697709)
1. Recombinant varicella-zoster virus glycoproteins E and I: immunologic responses and clearance of virus in a guinea pig model of chronic uveitis. Kimura H; Wang Y; Pesnicak L; Cohen JI; Hooks JJ; Straus SE; Williams RK J Infect Dis; 1998 Aug; 178(2):310-7. PubMed ID: 9697709 [TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of a recombinant varicella-zoster virus gE-IE63 fusion protein, a putative vaccine candidate against primary infection and zoster reactivation. Jacquet A; Haumont M; Massaer M; Garcia L; Mazzu P; Daminet V; Grégoire D; Jacobs P; Bollen A Vaccine; 2002 Feb; 20(11-12):1593-602. PubMed ID: 11858867 [TBL] [Abstract][Full Text] [Related]
3. Immunity in strain 2 guinea-pigs inoculated with vaccinia virus recombinants expressing varicella-zoster virus glycoproteins I, IV, V or the protein product of the immediate early gene 62. Lowry PW; Solem S; Watson BN; Koropchak CM; Thackray HM; Kinchington PR; Ruyechan WT; Ling P; Hay J; Arvin AM J Gen Virol; 1992 Apr; 73 ( Pt 4)():811-9. PubMed ID: 1321876 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of glycoprotein E subunit and live attenuated varicella-zoster virus vaccines formulated with a single-strand RNA-based adjuvant. Lee SJ; Park HJ; Ko HL; Lee JE; Lee HJ; Kim H; Nam JH Immun Inflamm Dis; 2020 Jun; 8(2):216-227. PubMed ID: 32167678 [TBL] [Abstract][Full Text] [Related]
5. Ability of yeast Ty-VLPs (virus-like particles) containing varicella-zoster virus (VZV)gE and assembly protein fragments to induce in vitro proliferation of human lymphocytes from VZV immune patients. Welsh MD; Harper DR; Garcia-Valcarcel M; Fowler WJ; Aitken C; Jeffries DJ; Layton GT J Med Virol; 1999 Sep; 59(1):78-83. PubMed ID: 10440812 [TBL] [Abstract][Full Text] [Related]
7. Immunization with recombinant varicella-zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs. Heineman TC; Connelly BL; Bourne N; Stanberry LR; Cohen J J Virol; 1995 Dec; 69(12):8109-13. PubMed ID: 7494331 [TBL] [Abstract][Full Text] [Related]
8. Identification of viral antigens recognized by ocular infiltrating T cells from patients with varicella zoster virus-induced uveitis. Milikan JC; Kinchington PR; Baarsma GS; Kuijpers RW; Osterhaus AD; Verjans GM Invest Ophthalmol Vis Sci; 2007 Aug; 48(8):3689-97. PubMed ID: 17652740 [TBL] [Abstract][Full Text] [Related]
9. Induction of neutralizing antibody and T-cell responses to varicella-zoster virus (VZV) using Ty-virus-like particles carrying fragments of glycoprotein E (gE). Garcia-Valcarcel M; Fowler WJ; Harper DR; Jeffries DJ; Layton GT Vaccine; 1997; 15(6-7):709-19. PubMed ID: 9178473 [TBL] [Abstract][Full Text] [Related]
10. Characterization of the varicella zoster virus (VZV)-specific intra-ocular T-cell response in patients with VZV-induced uveitis. Milikan JC; Kuijpers RW; Baarsma GS; Osterhaus AD; Verjans GM Exp Eye Res; 2006 Jul; 83(1):69-75. PubMed ID: 16530754 [TBL] [Abstract][Full Text] [Related]
11. The synthesis and immunogenicity of varicella-zoster virus glycoprotein E and immediate-early protein (IE62) expressed in recombinant herpes simplex virus-1. Lowry PW; Koropchak CM; Choi CY; Mocarski ES; Kern ER; Kinchington PR; Arvin AM Antiviral Res; 1997 Feb; 33(3):187-200. PubMed ID: 9037375 [TBL] [Abstract][Full Text] [Related]
12. Efficient induction of cell-mediated immunity to varicella-zoster virus glycoprotein E co-lyophilized with a cationic liposome-based adjuvant in mice. Wui SR; Kim KS; Ryu JI; Ko A; Do HTT; Lee YJ; Kim HJ; Lim SJ; Park SA; Cho YJ; Kim CG; Lee NG Vaccine; 2019 Apr; 37(15):2131-2141. PubMed ID: 30827737 [TBL] [Abstract][Full Text] [Related]
13. Immune response to vaccinia virus recombinants expressing glycoproteins gE, gB, gH, and gL of Varicella-zoster virus. Kutinová L; Hainz P; Ludvíková V; Maresová L; Nĕmecková S Virology; 2001 Feb; 280(2):211-20. PubMed ID: 11162835 [TBL] [Abstract][Full Text] [Related]
14. Construction of Oka varicella vaccine expressing human immunodeficiency virus env antigen. Shiraki K; Sato H; Yoshida Y; Yamamura JI; Tsurita M; Kurokawa M; Kageyama S J Med Virol; 2001 Jun; 64(2):89-95. PubMed ID: 11360239 [TBL] [Abstract][Full Text] [Related]
15. Immunogenicity in mice of varicella-zoster virus glycoprotein I expressed by a vaccinia virus-varicella-zoster virus recombinant. Ludvíková V; Kunke D; Hamsíková E; Kutinová L; Vonka V J Gen Virol; 1991 Jun; 72 ( Pt 6)():1445-9. PubMed ID: 1646285 [TBL] [Abstract][Full Text] [Related]
16. Experimental infection and immune response of guinea pigs with varicella-zoster virus. Matsunaga Y; Yamanishi K; Takahashi M Infect Immun; 1982 Aug; 37(2):407-12. PubMed ID: 6288560 [TBL] [Abstract][Full Text] [Related]
17. Stability of a varicella-zoster virus glycoprotein E epitope. Vafai A; Forghani B; Kilpatrick D; Ling J; Shankar V Arch Virol; 2000; 145(1):85-97. PubMed ID: 10664408 [TBL] [Abstract][Full Text] [Related]
18. Varicella-Zoster virus proteins encoded by open reading frames 14 and 67 are both dispensable for the establishment of latency in a rat model. Grinfeld E; Sadzot-Delvaux C; Kennedy PG Virology; 2004 May; 323(1):85-90. PubMed ID: 15165821 [TBL] [Abstract][Full Text] [Related]